Yesterday an MRI exam on Derek Jeter’s surgically repaired ankle showed mild inflammation after he complained of soreness and today the Yankees shortstop got a cortisone injection.
General manager Brian Cashman stressed that the setback isn’t a severe one, but also told Bryan Hoch of MLB.com that Jeter’s status for Opening Day could be in question:
The season is starting to approach. I know if you asked him, Opening Day would be a certainty. In fairness, I don’t know yet. He’s got to be in position where he could play a full nine innings of defense, be able to do back-to-back [games] and other stuff. There’s some time left. We’ll see how he responds, but I can’t give you certainty.
Players typically take at least a few days off following cortisone injections even if they’re feeling good, at which point Jeter would have about a week to get himself ready for Game 1.
Former Angels outfielder Jabari Blash has signed a one-year deal with the Tohoku Rakuten Golden Eagles of Nippon Professional Baseball, the team announced Friday. Per the Japan Times, the deal is said to be worth around $1.06 million. Blash was released from his contract with the Angels at the end of November.
The 29-year-old outfielder has had a rough go of it in the majors, where he failed to duplicate the promising results he delivered in the minors. While he consistently batted above .250 with 20-30 home runs per season at the Double- and Triple-A level, he petered out in back-to-back gigs with the Padres and Angels and slumped toward a .103/.200/.128 finish across 45 PA for Anaheim in 2018.
The hope, of course, is that the environment in NPB will help him get a better handle on his issues at the plate — in a best case scenario, resulting in a full-scale transformation that could make him more marketable to MLB teams in the future. To that end, Blash expects to be utilized as a cleanup batter in the Eagles’ lineup and will focus on assisting the club as they make a run toward the Japan Series.